Cargando…

Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet

OBJECTIVE: The aim of this study was to investigate whether the modified Atkins diet (MAD), a variant of the ketogenic diet, has an impact on bone‐ and calcium (Ca) metabolism. METHODS: Two groups of adult patients with pharmacoresistant epilepsy were investigated. One, the diet group (n = 53), was...

Descripción completa

Detalles Bibliográficos
Autores principales: Molteberg, Ellen, Taubøll, Erik, Kverneland, Magnhild, Iversen, Per Ole, Selmer, Kaja Kristine, Nakken, Karl Otto, Hofoss, Dag, Thorsby, Per Medbøe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304173/
https://www.ncbi.nlm.nih.gov/pubmed/35092022
http://dx.doi.org/10.1111/epi.17169
_version_ 1784752042477092864
author Molteberg, Ellen
Taubøll, Erik
Kverneland, Magnhild
Iversen, Per Ole
Selmer, Kaja Kristine
Nakken, Karl Otto
Hofoss, Dag
Thorsby, Per Medbøe
author_facet Molteberg, Ellen
Taubøll, Erik
Kverneland, Magnhild
Iversen, Per Ole
Selmer, Kaja Kristine
Nakken, Karl Otto
Hofoss, Dag
Thorsby, Per Medbøe
author_sort Molteberg, Ellen
collection PubMed
description OBJECTIVE: The aim of this study was to investigate whether the modified Atkins diet (MAD), a variant of the ketogenic diet, has an impact on bone‐ and calcium (Ca) metabolism. METHODS: Two groups of adult patients with pharmacoresistant epilepsy were investigated. One, the diet group (n = 53), was treated with MAD for 12 weeks, whereas the other, the reference group (n = 28), stayed on their habitual diet in the same period. All measurements were performed before and after the 12 weeks in both groups. We assessed bone health by measuring parathyroid hormone (PTH), Ca, 25‐OH vitamin D (25‐OH vit D), 1,25‐OH vitamin D (1,25‐OH vit D), phosphate, alkaline phosphatase (ALP), and the bone turnover markers procollagen type 1 N‐terminal propeptide (P1NP) and C‐terminal telopeptide collagen type 1 (CTX‐1). In addition, we examined the changes of sex hormones (estradiol, testosterone, luteinizing hormone, follicle‐stimulating hormone), sex hormone‐binding globulin, and leptin. RESULTS: After 12 weeks of MAD, we found a significant reduction in PTH, Ca, CTX‐1, P1NP, 1,25‐OH vit D, and leptin. There was a significant increase in 25‐OH vit D. These changes were most pronounced among patients <37 years old, and in those patients with the highest body mass index (≥25.8 kg/m²), whereas sex and type of antiseizure medication had no impact on the results. For the reference group, the changes were nonsignificant for all the analyses. In addition, the changes in sex hormones were nonsignificant. SIGNIFICANCE: Twelve weeks of MAD treatment leads to significant changes in bone and Ca metabolism, with a possible negative effect on bone health as a result. A reduced level of leptin may be a triggering mechanism. The changes could be important for patients on MAD, and especially relevant for those patients who receive treatment with MAD at an early age before peak bone mass is reached.
format Online
Article
Text
id pubmed-9304173
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93041732022-07-28 Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet Molteberg, Ellen Taubøll, Erik Kverneland, Magnhild Iversen, Per Ole Selmer, Kaja Kristine Nakken, Karl Otto Hofoss, Dag Thorsby, Per Medbøe Epilepsia Research Article OBJECTIVE: The aim of this study was to investigate whether the modified Atkins diet (MAD), a variant of the ketogenic diet, has an impact on bone‐ and calcium (Ca) metabolism. METHODS: Two groups of adult patients with pharmacoresistant epilepsy were investigated. One, the diet group (n = 53), was treated with MAD for 12 weeks, whereas the other, the reference group (n = 28), stayed on their habitual diet in the same period. All measurements were performed before and after the 12 weeks in both groups. We assessed bone health by measuring parathyroid hormone (PTH), Ca, 25‐OH vitamin D (25‐OH vit D), 1,25‐OH vitamin D (1,25‐OH vit D), phosphate, alkaline phosphatase (ALP), and the bone turnover markers procollagen type 1 N‐terminal propeptide (P1NP) and C‐terminal telopeptide collagen type 1 (CTX‐1). In addition, we examined the changes of sex hormones (estradiol, testosterone, luteinizing hormone, follicle‐stimulating hormone), sex hormone‐binding globulin, and leptin. RESULTS: After 12 weeks of MAD, we found a significant reduction in PTH, Ca, CTX‐1, P1NP, 1,25‐OH vit D, and leptin. There was a significant increase in 25‐OH vit D. These changes were most pronounced among patients <37 years old, and in those patients with the highest body mass index (≥25.8 kg/m²), whereas sex and type of antiseizure medication had no impact on the results. For the reference group, the changes were nonsignificant for all the analyses. In addition, the changes in sex hormones were nonsignificant. SIGNIFICANCE: Twelve weeks of MAD treatment leads to significant changes in bone and Ca metabolism, with a possible negative effect on bone health as a result. A reduced level of leptin may be a triggering mechanism. The changes could be important for patients on MAD, and especially relevant for those patients who receive treatment with MAD at an early age before peak bone mass is reached. John Wiley and Sons Inc. 2022-01-28 2022-04 /pmc/articles/PMC9304173/ /pubmed/35092022 http://dx.doi.org/10.1111/epi.17169 Text en © 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Article
Molteberg, Ellen
Taubøll, Erik
Kverneland, Magnhild
Iversen, Per Ole
Selmer, Kaja Kristine
Nakken, Karl Otto
Hofoss, Dag
Thorsby, Per Medbøe
Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet
title Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet
title_full Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet
title_fullStr Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet
title_full_unstemmed Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet
title_short Substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified Atkins diet
title_sort substantial early changes in bone and calcium metabolism among adult pharmacoresistant epilepsy patients on a modified atkins diet
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304173/
https://www.ncbi.nlm.nih.gov/pubmed/35092022
http://dx.doi.org/10.1111/epi.17169
work_keys_str_mv AT moltebergellen substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT taubøllerik substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT kvernelandmagnhild substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT iversenperole substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT selmerkajakristine substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT nakkenkarlotto substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT hofossdag substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet
AT thorsbypermedbøe substantialearlychangesinboneandcalciummetabolismamongadultpharmacoresistantepilepsypatientsonamodifiedatkinsdiet